BiVictriX Therapeutics PLC (GB:BVX) has released an update.
BiVictriX Therapeutics PLC has reported positive interim results for the first half of 2024, including promising preclinical safety and efficacy data for its lead drug, BVX001, targeting Acute Myeloid Leukaemia (AML). The company has secured FDA Orphan Drug Designation for BVX001, bolstering its regulatory and commercial prospects, and is also advancing BVX002 for solid tumours with support from an Innovate UK grant. With a focus on bispecific ADCs that offer improved cancer selectivity and safety, BiVictriX continues to expand its target discovery platform, addressing multiple cancer types and maintaining a strong cash position.
For further insights into GB:BVX stock, check out TipRanks’ Stock Analysis page.
